Prof David Bowtell
Honorary Conjoint Professorial Fellow
The Sir Peter MacCallum Department of Oncology
400 Scholarly works
55 Projects
HIGHLIGHTS
2024
Journal article
BRCA1 secondary splice-site mutations drive exon-skipping and PARP inhibitor resistance
DOI: 10.1186/s12943-024-02048-12022
Research grants (ARC, NHMRC, MRFF)
Driving Improvements in Ovarian Cancer Survival Through Molecular and Clinical Studies
2020
Research grants (ARC, NHMRC, MRFF)
Super-Next: Complete Genome Profiling for Cancer of Unknown Primary
2020
Research grants (ARC, NHMRC, MRFF)
Evaluation of Fibroblastic Activation Protein Inhibitors (FAPI) as a Novel Radiopharmaceutical Targeting Cancer-Associated Fibroblasts for the Diagnosis and Treatment of Patients With Cancer of Unknown Primary: The FAPI-CUP Trial
2018
Journal article
Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma
DOI: 10.1038/s41467-018-05564-z2017
Journal article
Secondary somatic mutations restoring RAD51C and RAD51D associated with acquired resistance to the PARP inhibitor rucaparib in high-grade ovarian carcinoma
DOI: 10.1158/2159-8290.CD-17-04192015
Journal article
Whole-genome characterization of chemoresistant ovarian cancer
DOI: 10.1038/nature14410
RECENT SCHOLARLY WORKS
2026
Journal article
Clinicopathologic and molecular predictors of survival in BRCA-deficient tubo-ovarian high-grade serous carcinoma.
DOI: 10.1038/s41467-026-71134-32026
Journal article
Real-world comparative outcomes of neoadjuvant chemotherapy with interval cytoreductive surgery versus primary cytoreductive surgery in epithelial ovarian cancer: insights from the australian ovarian cancer study (AOCS)
DOI: 10.1016/j.ijgc.2025.1030762026
Journal article
Rethinking ovarian cancer III: the past decade and future directions
DOI: 10.1038/s41568-026-00916-02025
Journal article
762MO Clinical whole genome and transcriptome sequencing for cancer of unknown primary: An Australian prospective observational study
DOI: 10.1016/j.annonc.2025.10.11772025
Journal article
Overcoming intra-tumoral heterogeneity for biomarker discovery in the high-grade serous ovarian cancer proteome
DOI: 10.1038/s41698-025-00911-y2025
Other
Supplementary Figures S1-S4 from The Prognostic Effect of Immune Cell Infiltration Depends on Molecular Subtype in Endometrioid Ovarian Carcinomas
DOI: 10.1158/1078-0432.307085052025
Other
Supplementary Tables S1-S5 from The Prognostic Effect of Immune Cell Infiltration Depends on Molecular Subtype in Endometrioid Ovarian Carcinomas
DOI: 10.1158/1078-0432.307085022025
Other
Supplementary Data from Epithelial-to-Mesenchymal Transition Supports Ovarian Carcinosarcoma Tumorigenesis and Confers Sensitivity to Microtubule Targeting with Eribulin
DOI: 10.1158/0008-5472.30699401